Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

DOI Full Paper Access

108

Citations

40

References

2016

Year

Patricia LoRusso, Jing Li, Angelika M. Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney,

Clinical Cancer Research

Abstract

Veliparib can be safely combined with irinotecan at doses that inhibit PARP catalytic activity. Preliminary antitumor activity justifies further evaluation of the combination. Clin Cancer Res; 22(13); 3227-37. ©2016 AACR.

References

	Year	Citations

Page 1